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Abstract  
Objectives: Dermatitis herpetiformis (DH) is a cutaneous manifestation of coeliac 
disease. Bone fracture risk is increased in coeliac disease, but little knowledge exists 
about bone complications in DH. This study aimed to evaluate the risk of hip and other 
hospital-treated fractures in DH and coeliac disease in a high prevalence area with good 
adherence to a gluten-free diet.  
Materials and methods: Hip, proximal humerus, wrist and ankle fractures in 368 treated 
DH and 1,076 coeliac disease patients between 1970 and 2015 were reviewed from the 
National Hospital Discharge Register. Hip fracture incidence rates for DH and coeliac 
disease patients were compared to those for the general population. The overall fracture 
risk for DH was compared to coeliac disease. 
Results: The hip fracture incidence rates for DH and coeliac disease patients did not 
differ from the general population. In females aged 80–89, the hip fracture incidence was 
higher in DH than in coeliac disease, but the risk for any hospital-treated fracture was 
lower in DH compared to coeliac disease (adjusted HR 0.620, 95% CI 0.429–0.949). The 
DH and coeliac disease patients with hospital-treated fractures were diagnosed at an older 
age, but the degree of small bowel mucosal damage did not significantly differ between 
patients with and without fractures.  
Conclusion: The incidence of hip fracture is not increased in treated DH or coeliac 
disease in an area with high awareness and dietary compliance rates. However, patients 
with DH seem to have lower risk for fractures overall compared to coeliac disease. 
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Introduction 
 
Coeliac disease is an immune-mediated enteropathy triggered by dietary gluten affecting 
1–2% of the population.1 Although the disease is classically known as a malabsorption 
syndrome presenting with gastrointestinal symptoms, presently a wide range of 
extraintestinal symptoms are increasingly common.1 Dermatitis herpetiformis (DH), a 
cutaneous manifestation of coeliac disease, presents in approximately 13% of coeliac 
disease patients.2 In DH gluten induces a blistering, itchy rash with pathognomonic 
granular dermal immunoglobulin (Ig) A deposits. DH patients also suffer from coeliac-
type small bowel mucosal villous atrophy or inflammation, and circulating and intestinal 
IgA class antibodies against transglutaminase 2  at diagnosis are characteristic for both 
DH and coeliac disease.1,3 A strict life-long gluten-free diet (GFD) is the treatment of 
choice for both disorders and the diet heals the small bowel mucosal changes and 
alleviates the DH rash.1,3 However, the diet is frequently considered restrictive and 
difficult to comply with, and the adherence to a strict GFD have ranged from 42% to 91% 
in different study populations.4 
 
Coeliac disease has been linked to decreased bone mineral density (BMD)5 and also to 
increased any-type and hip fracture risk6, which have been at least partly explained by the 
small bowel mucosal damage. GFD treatment recognizably increases BMD in coeliac 
disease5, and has a preventive effect against bone fractures.7 Knowledge concerning bone 
complications in DH is currently scant, but since the small bowel mucosal damage is 
more subtle than in coeliac disease, it seems probable that bone deterioration and fracture 
risk is more minor than in coeliac disease. Two studies have found a lower BMD in DH 
than in controls, but better than in patients with coeliac disease,8,9 and three studies found 
no difference in BMD between DH patients and healthy controls.10–12 The only published 
register-based fracture study on patients with DH thus far did not find increased fracture 
risk associated with DH.13 
 
The aim of this register-based study was to evaluate whether patients with DH and 
coeliac disease have an increased incidence of hip fractures compared to the general 
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population in an area with high rate of clinically diagnosed cases14 and with good dietary 
compliance rates.15,16 A further aim was to compare any-type hospital-treated fractures 
between patients with DH and coeliac disease to determine whether the fracture risk 
varies between these two manifestations of the same disease. This knowledge is of 
importance when considering the need for BMD measurements in DH and coeliac 
disease. 
Materials and methods 
Study population 
Long term follow-up data were obtained by enrolling all patients diagnosed with DH 
between the years 1969 and 2000 at the Department of Dermatology at Tampere 
University Hospital. The department has a special outpatient clinic for patients with DH, 
where all DH patients within the catchment area of the hospital district are diagnosed. 
The DH diagnosis of each patient relied on clinical symptoms compatible with DH and 
demonstration of dermal IgA with direct immunofluorescence examination.17 The coeliac 
disease study group comprised all patients in the Tampere area with a small bowel 
biopsy-based diagnosis made during the same time period as the patients with DH. All 
patients with a DH diagnosis were excluded from the coeliac disease study group, which 
thereafter included patients with any other phenotype of coeliac disease than DH. 
Furthermore, the patients diagnosed with coeliac disease for more than one year prior to a 
DH diagnosis were excluded from the DH study group. Eventually, our DH study cohort 
comprised 368 patients, and the coeliac disease cohort 1,076 patients.  
 
After the diagnosis, all DH and coeliac disease patients were advised to adhere to a strict 
GFD. In addition, DH patients with severe skin symptoms were prescribed dapsone 
medication to alleviate the intense itching more quickly. The patients with DH were 
followed up at the Department of Dermatology for at least 1–2 years or until the dapsone 
treatment was discontinued, and coeliac disease patients were followed up either in 
primary or tertiary care, depending on the severity of the disease.  
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Study design 
For both cohorts, the findings of small bowel mucosal specimens at diagnosis were 
gathered from the medical records. The data on hospital-treated fractures were obtained 
from the Finnish National Hospital Discharge Register (NHDR). This mandatory register 
for all hospitals is maintained by the National Institute for Health and Welfare. The 
database contains variables such as hospital admission and discharge days, primary and 
secondary diagnosis with ICD-coding (ICD-8 for 1969–1986, ICD-9 for 1987–1995, and 
ICD-10 since 1996), and all procedures performed during the stay.  
 
The data on inpatient treatment periods were gathered from the NHDR for both cohorts 
for the time period of 1970–2015. The main outcome was the first hospital-treated hip 
fracture defined with the relevant ICD-8–10 codes (N820*, 820*, S72*). The hip fracture 
was chosen as the main outcome because these fractures are practically always treated in 
the hospital, ensuring comprehensive fracture data deriving from the NHDR. Also, data 
about the first proximal humerus fracture (N812.0, N812.1, 812*, S42.2), the first wrist 
fracture (N813.4, N813.5, N814.0, N814.1, 813*, S52.5, S52.6) and the first ankle 
fracture (N824*, 824*, S82.5, S82.6, S82.8) causing hospital treatment periods were 
collected. The dates of death or emigration for the study patients were obtained from the 
Population Register Centre of Finland. The follow-up time began from the time of the 
DH or coeliac disease diagnosis or – for those diagnosed before 1970 – on the 1 January 
1970. The follow-up ended on the date of the first discharge diagnosis for the studied 
fracture, the date of the subject’s death or emigration, or the end of the study period (31 
December 2015), whichever occurred first.  
 
The age- and gender-distributed incidence rates of hospital-treated hip fractures in the 
Finnish population were reported in the National Institute for Health and Welfares report 
concerning the quality of joint replacement surgery in Finland for 2014.18 These 
incidences were used in this study as the general population comparison incidences.  
 
The study protocol was approved by the Regional Ethics Committee of Tampere 
University Hospital (R16090, October 11th, 2016) and is in accordance with the 
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Declaration of Helsinki. In register-based studies the consent from patients is not 
obtained. 
Statistical analysis 
The continuous variables were described with median values and interquartile ranges 
(IQR), and the categorized values as numbers and percentages. The 95% confidence 
intervals (CI) were calculated for fracture incidence rates assuming a Poisson 
distribution. The Mann–Whitney U test and the chi-squared test were used for comparing 
the groups. The Cox Proportional-Hazards Model was used for comparing the fracture 
risk between the patients with DH and coeliac disease. All testing was two-sided, and p < 
0.05 was considered statistically significant. All the statistical analyses were performed 
with the SPSS version 24 (IBM Corporation, Armonk, NY) in cooperation with a 
statistician. 
Results 
There was female predominance among the 1,076 coeliac disease patients, whereas the 
gender distribution was equal among the 368 DH patients (Table 1). The median age was 
higher in DH compared to the coeliac disease patients. The coeliac disease patients were 
more often diagnosed during childhood, and had more severe villous atrophy at diagnosis 
compared to DH patients (Table 1). In total, 27% of the patients with DH and 20% of the 
patients with coeliac disease died during the follow-up period and seven of the coeliac 
disease patients had moved to another country during the follow-up. 
 
Hip fractures had occurred in 14 (4%) patients with DH and 18 (2%) patients with coeliac 
disease. The median follow-up time for the first hip fracture was 28 years (IQR 21–34) in 
the DH cohort and 23 years (IQR 18–29) in the coeliac disease cohort, resulting in 10,003 
and 25,033 observed person-years at risk, respectively. Thus, the hip fracture incidences 
per 100,000 person-years were 140 (95% CI 77–235) in the DH and 72 (95% CI 43–114) 
in the coeliac disease cohort. Only one DH patient and four coeliac disease patients had 
suffered a hip fracture under the age of 70 years. Therefore, the hip fracture incidences 
were studied more specifically in males and females aged 70–79 and 80–89 years 
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(Figure 1). In total of 410 DH or coeliac disease patients were between the ages of 70 and 
89 in 2014, and one hip fracture had occurred in the DH cohort. After these individuals 
were subtracted from the general population values, the hip fracture incidences in the DH 
and coeliac disease cohorts did not differ from the general population in any subgroups. 
The incidences did not differ between DH and coeliac disease patients either, except that 
in the subgroup of females aged 80–89 years the hip fracture incidence was statistically 
significantly higher in DH than in coeliac disease cohort (2,435 (95% CI 893–5,300) and 
706 (95% CI 146–2,064) per 100,000 person-years, respectively; see Figure 1). In the DH 
cohort, older patients had been diagnosed at an older age compared to younger patients, 
since there was a negative correlation between the birth year and the age at the time of the 
diagnosis (r = -0.90, p < 0.001). 
 
Hip, proximal humerus, wrist or ankle fractures leading to hospitalization had occurred in 
35 (10%) DH and in 105 (10%) coeliac disease patients, resulting in an incidence rate of 
any-type hospital-treated fracture of 360 (95% CI 251–500) and 435 (95% CI 356–527) 
per 100,000 person-years, respectively. Patients with DH were at a lower overall risk for 
hospital-treated fractures compared to patients with coeliac disease when the risk was 
adjusted for gender and year of birth (Table 2). The adjusted hazard ratio for hip fractures 
as well as other hospital-treated fractures was also lower for patients with DH, but the 
difference was not statistically significant (Table 2). 
 
In both cohorts, there was a slight female predominance among those with fractures 
compared to those without, and the individuals with fractures were diagnosed with DH or 
coeliac disease at an older age (Table 3). Furthermore, the patients with a fracture in the 
DH cohort had been diagnosed with DH more formerly than those without (median 
diagnostic years 1981 and 1985, respectively, p = 0.056)). The degree villous atrophy did 
not significantly differ between those with and without fractures in either cohort, but 
coeliac disease patients with a fracture had more often subtotal or total villous atrophy at 
diagnosis compared to DH patients with a fracture (p < 0.001) (Table 3). 
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Discussion 
In this large register-based study, we found no increase in the incidence of hip fractures 
in those diagnosed with DH compared to the general population. Moreover, coeliac 
disease was not shown to associate with increased hip fracture incidence either. The 
patient cohorts in the current study were gathered from an area where prevalence of 
diagnosed DH and coeliac disease is high2,14 and adherence to GFD is excellent15,16, both 
of which are known to vary between different populations and undoubtedly have affected 
the results of previous fracture studies2,4,14,19,20. 
 
Prior to the current study, only one study has assessed the fracture risk in DH compared 
to the general population; it found no risk of hip or any-type fractures in DH.13 The hip 
fracture incidence in the DH group in that study was closely equal to that in the current 
study (143 and 140 per 100,000 person-years at risk, respectively), although the follow-
up time was rather short, and the population was younger than ours.13 In turn, the any-
type fracture risk has been shown to be increased in coeliac disease in the majority of the 
performed studies.6 Furthermore, in coeliac disease a 2- to 4-fold increase in the hip 
fracture risk has been detected21–23 although contrary results also exist24,25. A recent meta-
analysis found a slightly increased (30%) any-facture risk and a 69% increased hip 
fracture risk in coeliac disease patients6. Discordantly with the meta-analysis, we found 
no increase in the hip fracture risk in coeliac disease compared to the general population.  
 
In our previous study investigating self-reported fractures, the lifetime bone fracture risk 
was found to be equal between patients with DH and coeliac disease, except that females 
with coeliac disease had a higher fracture risk after being diagnosed compared to females 
with DH.26 In the current study, the hospital-treated fractures overall were increased in 
the coeliac disease cohort compared to the DH cohort, which is in line with our previous 
finding. However, females aged 80–89 in the DH cohort had an increased hip fracture 
incidence compared to the comparable coeliac disease cohort. 
 
Decreased BMD is a risk factor for bone fractures, and has been explained with a 
multifactorial aetiology in coeliac disease. The small bowel mucosal villous atrophy in 
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coeliac disease decreases the absorption of micronutrients necessary for bone 
metabolism.5 Also the decreased calcium absorption causing secondary 
hyperparathyroidism and the persistent inflammation are suggested to cause decreased 
BMD in patients with coeliac disease.5 Prolonged diagnostic delay, poor adherence to a 
GFD, and persistent villous atrophy are factors associated with increased fracture risk in 
coeliac disease.7,27,28 In Finland, the diagnostic delay has decreased over the past decades 
for both coeliac disease and DH.29,30 Also, the documented adherence to a strict GFD has 
been shown to be as high as 90% in DH and coeliac disease15,16, and persistent villous 
atrophy in coeliac disease is infrequent.31,32 These facts at least partly explain the 
currently found similar hip fracture incidence rates in the DH and coeliac disease cohorts 
compared to the general population. The detected higher overall fracture risk in coeliac 
disease compared to DH could instead be explained by the more severe villous atrophy 
associated with coeliac disease at the time of the diagnosis.  
 
In this study, DH patients with a fracture had been diagnosed earlier compared to patients 
without a fracture. We have previously shown that the severity of small bowel mucosal 
damage has become milder in DH33 and it is generally acknowledged that the importance 
of a strict adherence to GFD treatment over dapsone has increased during the last 
decades. Together with decreased diagnostic delay 30 the duration of gluten exposure has 
thus shortened among DH patients over time and this has most likely had an influence on 
the decreased fracture risk in those diagnosed with DH in recent times. Moreover, the 
diagnostic age, and subsequently also the gluten exposure time, of older DH patients in 
this study was higher than that of the younger ones, which might partly explain the higher 
hip fracture risk in females aged 80–89 years in the DH cohort compared to 
corresponding coeliac disease patients. 
 
This study with long follow-up times was conducted with large, well-defined cohorts of 
patients with biopsy-proven DH and coeliac disease with varying severities of the 
disease. The gender distributions of the study populations were corresponding  to that 
usually detected in DH and coeliac disease.3 A hospital-discharge register was used to 
identify the fractures, and the NHDR has proven to be a reliable source of medical data 
for epidemiologic studies and its quality and accuracy is well proven for hip fractures.34 
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Even though hospitalization related to proximal humerus, wrist and ankle fractures 
depends on several factors, such as the severity of the fracture, the operative current care 
guidelines, the results should be comparable between study groups, as we have no reason 
to assume vast dissimilarities in the treatment of fractures on the cohort level. A 
limitation is that in a register-based study, it is not possible to take into consideration 
various confounding factors such as lifestyle choices and use of medications and long-
term illnesses predisposing patients to fractures. In addition, there was no exact data 
available for the GFD adherence in the study cohorts. However, previously performed 
studies from the same area and consisting largely of the same DH and coeliac disease 
patients have shown >90% GFD adherence rates.16,35 Moreover, improved overall health 
status, increased body-mass index and an increase in functional ability among the elderly 
has been also observed in the Finnish population over time,36 and all of these factors 
contribute to preventing fractures. Nevertheless, these changes supposedly have affected 
both study cohorts and also the general population equally. Additionally, it must be 
emphasized that the general population incidence values were used as reference values 
for hip fractures instead of matched controls.  
 
To conclude, the risk of hip fractures is not increased in those diagnosed with DH or 
coeliac disease in an area where adherence to a GFD is good and persistent villous 
atrophy is infrequent. However, coeliac disease seems to be associated with a slightly 
higher overall fracture risk compared to DH. Based on these current results, there is no 
need for routine BMD measurements in DH and not even in coeliac disease. However, 
since coeliac disease is a known risk factor for fractures, especially in individuals with 
prolonged diagnosis and in those diagnosed at an old age, the necessity of bone 
investigations should be considered but still individually assessed based on all of the 
existing risk factors for fractures. Worth noticing is, however, that the need for BMD 
evaluation seems to be of higher importance in coeliac disease than in DH. 
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Table 1. Demographic data and small bowel mucosal histology at the time of diagnosis 
for the dermatitis herpetiformis (DH) and coeliac disease study cohorts. 
  DH patients   
(n=368) 
Coeliac disease 
patients (n=1,076) 
Female, %* 49 68 
Year of birth, median (IQR) * 1946 (1933–1957) 1952 (1940–1967) 
Age at diagnosis, %*   
 Under 18 years 5 21 
 18 to 50 years 67 52 
 Over 50 years 29 26 
Small bowel histology at diagnosis, %*   
 Normal 29 0 
 PVA 29 25 
 SVA/TVA 42 75 
Age at the end of the follow-up, median 
(IQR), years* 
67 (57–76) 60 (47–71) 
IQR; Interquartile range, PVA; Partial villous atrophy, SVA/TVA; Subtotal/Total villous 
atrophy 
* p < 0.001 between DH and coeliac disease patients 
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Table 2. Adjusted hazard ratios (HR) with 95% confidence intervals (CI) for hospital-
treated fractures in dermatitis herpetiformis patients compared to coeliac disease patients. 
  Adjusteda HR (95% CI) 
All hospital-treated fractures b 0.620 (0.429–0.949) * 
 
Hip fracture 0.803 (0.384–1.678) 
 
Other fractures c 0.661 (0.423–1.034)  
aAdjusted for gender and year of birth  
bHip, proximal humerus, wrist and ankle fractures combined  
cProximal humerus, wrist and ankle fractures  
* p = 0.026 
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Table 3. Demographic and clinical data of dermatitis herpetiformis (DH) and coeliac disease patients with and without fractures. 
  DH patients (n=368)  Coeliac disease patients (n=1,076) 
 With fracture 
(n=35) 
Without fracture 
(n=333) 
p-value  With fracture 
(n=105) 
Without fracture 
(n=971) 
p-value 
Female, % 63 47 0.083  75 67 0.095 
Age at DH or coeliac 
disease diagnosis, 
median (IQR), years 
54 (35–60) 37 (28–50) 0.002  45 (34–58) 37 (19–50) <0.001 
Year of diagnosis, 
median (IQR) 
1981 (1976–1989) 1985 (1980–1991) 0.056  1990 (1985–1996) 1990 (1985–1996) 0.893 
Age at the end of the 
follow-up, median (IQR), 
years 
71 (56–80) 67 (57–75) 0.309  59 (47–70) 60 (47–71) 0.594 
Small bowel histology at 
diagnosis, % 
  0.070    0.082 
 Normal 46 28   0 0  
 PVA 14 30   16 26  
 SVA/TVA 39 42   84 74  
IQR; Interquartile range, PVA; Partial villous atrophy, SVA/TVA; Subtotal/Total villous atrophy 
 
 
18 
 
 
 
 
Figure 1. The age- and gender-specific hip fracture incidence rates and 95% confidence intervals for dermatitis  
herpetiformis (DH) and coeliac disease patients, and the general population of Finland. 
